Impact	O
of	O
technology	O
on	O
the	O
utilisation	O
of	O
positron	O
emission	O
tomography	O
in	O
lymphoma	B-Cancer
:	O
current	O
and	O
future	O
perspectives	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
has	O
now	O
gained	O
a	O
place	O
in	O
the	O
management	O
of	O
patients	O
with	O
cancer	B-Cancer
,	O
including	O
those	O
with	O
Hodgkin	O
'	O
s	O
disease	O
and	O
non	B-Cancer
-	I-Cancer
Hodgkin	I-Cancer
'	I-Cancer
s	I-Cancer
lymphoma	I-Cancer
.	O

Restaging	O
studies	O
and	O
those	O
addressing	O
the	O
monitoring	O
of	O
response	O
to	O
treatment	O
are	O
especially	O
in	O
focus	O
.	O

Most	O
of	O
the	O
knowledge	O
gained	O
has	O
been	O
achieved	O
with	O
dedicated	O
BGO	O
-	O
based	O
PET	O
technology	O
,	O
but	O
there	O
are	O
a	O
number	O
of	O
developments	O
that	O
will	O
impact	O
on	O
the	O
use	O
of	O
this	O
metabolic	O
imaging	O
technique	O
in	O
the	O
investigation	O
of	O
patients	O
with	O
lymphoma	B-Cancer
.	O

The	O
challenges	O
ahead	O
are	O
determined	O
by	O
the	O
need	O
for	O
high	O
-	O
quality	O
whole	O
-	O
body	O
imaging	O
associated	O
with	O
increased	O
patient	O
throughput	O
and	O
the	O
need	O
to	O
investigate	O
the	O
role	O
of	O
new	O
labelled	O
ligands	O
.	O

The	O
latter	O
are	O
likely	O
to	O
yield	O
new	O
insights	O
into	O
tumour	B-Cell
cell	I-Cell
characterisation	O
,	O
tumour	B-Cancer
behaviour	O
and	O
tumour	B-Cancer
outcome	O
assessment	O
.	O

The	O
study	O
of	O
new	O
radiolabelled	O
ligands	O
will	O
impose	O
further	O
demands	O
for	O
rapid	O
dynamic	O
data	O
acquisition	O
and	O
accurate	O
tracer	O
quantification	O
.	O

Current	O
and	O
future	O
developments	O
in	O
PET	O
technology	O
range	O
from	O
the	O
use	O
of	O
new	O
detector	O
materials	O
to	O
different	O
detector	O
geometries	O
and	O
data	O
acquisition	O
modes	O
.	O

The	O
search	O
for	O
alternatives	O
to	O
BGO	O
scintillation	O
materials	O
for	O
PET	O
has	O
led	O
to	O
the	O
development	O
of	O
PET	O
instruments	O
utilising	O
new	O
crystals	O
such	O
as	O
LSO	O
and	O
GSO	O
.	O

The	O
use	O
of	O
these	O
new	O
detectors	O
and	O
the	O
increased	O
sensitivity	O
achieved	O
with	O
3D	O
data	O
acquisitions	O
represent	O
the	O
most	O
significant	O
current	O
developments	O
in	O
the	O
field	O
.	O

With	O
the	O
increasing	O
demands	O
imposed	O
on	O
the	O
clinical	O
utilisation	O
of	O
PET	O
,	O
issues	O
such	O
as	O
study	O
cost	O
and	O
patient	O
throughput	O
will	O
emerge	O
as	O
significant	O
future	O
factors	O
.	O

As	O
a	O
consequence	O
,	O
low	O
-	O
cost	O
units	O
are	O
being	O
offered	O
by	O
the	O
manufacturers	O
through	O
the	O
utilisation	O
of	O
gamma	O
camera	O
-	O
based	O
SPET	O
systems	O
for	O
PET	O
coincidence	O
imaging	O
.	O

Unfortunately	O
,	O
clinical	O
studies	O
in	O
lymphoma	B-Cancer
and	O
other	O
cancers	B-Cancer
have	O
already	O
demonstrated	O
the	O
limitations	O
of	O
this	O
technology	O
,	O
with	O
20	O
%	O
of	O
lesions	B-Cancer
<	O
15	O
mm	O
in	O
size	O
escaping	O
detection	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
recent	O
development	O
of	O
combined	O
PET	O
/	O
CT	O
devices	O
attempts	O
to	O
address	O
the	O
lack	O
of	O
anatomical	O
information	O
inherent	O
with	O
PET	O
images	O
,	O
taking	O
advantage	O
of	O
further	O
improvement	O
in	O
patient	O
throughput	O
and	O
hence	O
cost	O
-	O
effectiveness	O
.	O

Preliminary	O
studies	O
using	O
this	O
multimodality	O
imaging	O
approach	O
have	O
already	O
demonstrated	O
the	O
potential	O
of	O
the	O
technique	O
.	O

Although	O
the	O
potential	O
exists	O
,	O
certain	O
technical	O
issues	O
with	O
PET	O
/	O
CT	O
require	O
refinement	O
of	O
the	O
methodology	O
.	O

Such	O
issues	O
include	O
organ	B-Organ
movement	O
(	O
such	O
as	O
respiratory	B-Anatomical_system
motion	O
)	O
,	O
which	O
strongly	O
influences	O
the	O
image	O
fusion	O
of	O
a	O
rapidly	O
acquired	O
CT	O
scan	O
with	O
the	O
slower	O
acquisition	O
of	O
a	O
PET	O
dataset	O
,	O
and	O
the	O
derivation	O
of	O
CT	O
-	O
based	O
attenuation	O
coefficients	O
in	O
the	O
presence	O
of	O
contrast	O
agents	O
or	O
metallic	O
implants	O
.	O

The	O
application	O
of	O
the	O
technology	O
for	O
radiotherapy	O
planning	O
also	O
poses	O
a	O
number	O
of	O
associated	O
challenges	O
.	O

Finally	O
,	O
the	O
development	O
of	O
dedicated	O
PET	O
systems	O
based	O
on	O
planar	O
detector	O
arrangements	O
with	O
new	O
detector	O
components	O
has	O
the	O
potential	O
to	O
improve	O
clinical	O
throughput	O
by	O
over	O
100	O
%	O
,	O
but	O
clinical	O
trials	O
using	O
such	O
systems	O
have	O
still	O
to	O
be	O
carried	O
out	O
in	O
order	O
to	O
establish	O
the	O
associated	O
whole	O
-	O
body	B-Organism_subdivision
image	O
quality	O
.	O

